Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsLøhmann, Ditte J A
Jónsson, Ólafur G
MetadataShow full item record
CitationEffect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.Haematologica. 2016, 101(11):1359-1367
AbstractTreatment for pediatric acute myeloid leukemia is very toxic and the association between outcome and age and body mass index is unclear. We investigated effect of age and body mass index on toxicity and survival in pediatric acute myeloid leukemia. We studied all patients who completed first induction course of NOPHO-AML 2004 (n=318). Toxicity following induction and consolidation courses (n=6) was analyzed. The probabilities of toxicity and death were determined using time-to-event analyses with Cox multivariate proportional hazard regression for comparative analyses. Age 10-17 years was associated with sepsis with hypotension (hazard ratio 2.3 (95% confidence interval 1.1-4.6)). Overweight (>1 standard deviation) was associated with requiring supplemental oxygen (1.9 (1.0-3.5)). The 5-year event-free and overall survival were 47 % and 71%. Children aged 10-17 years showed a trend for inferior 5-year overall survival compared to children aged 2-9 (64% versus 76%, p=0.07). Infants showed a trend for superior 5-year event-free survival (66% versus 43%, p=0.06). Overweight children aged 10-17 showed a trend for superior survival (5-year event-free survival 59% versus 40%, p=0.09 and 5-year overall survival 78% versus 56%, p=0.06) compared to healthy weight children aged 10-17. In conclusion children aged 10-17 and overweight children had a higher risk of grade 3-4 toxicity. Children aged 10-17 showed inferior survival, but, unexpectedly, in this age group overweight children tended to have increased survival. This suggests different pharmacokinetics of chemotherapeutic drugs in adolescents and warrants further studies.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to Haematologica
- Mortality in overweight and underweight children with acute myeloid leukemia.
- Authors: Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA
- Issue date: 2005 Jan 12
- Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.
- Authors: Nasir SS, Giri S, Nunnery S, Martin MG
- Issue date: 2017 Feb
- Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
- Authors: Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H
- Issue date: 2001 May 15
- Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
- Authors: Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K
- Issue date: 2018 Jan
- Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
- Authors: Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R
- Issue date: 2014 Sep 20